We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Hologic (HOLX - Free Report) closed at $69.64 in the latest trading session, marking a +0.9% move from the prior day. This move outpaced the S&P 500's daily gain of 0.34%.
Prior to today's trading, shares of the medical device maker had gained 14.05% over the past month. This has outpaced the Medical sector's gain of 2.22% and the S&P 500's gain of 2.71% in that time.
Investors will be hoping for strength from HOLX as it approaches its next earnings release, which is expected to be July 28, 2021. In that report, analysts expect HOLX to post earnings of $1.12 per share. This would mark year-over-year growth of 49.33%. Our most recent consensus estimate is calling for quarterly revenue of $1.03 billion, up 25.69% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.72 per share and revenue of $5.11 billion, which would represent changes of +93.97% and +35.36%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for HOLX. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.42% lower. HOLX is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, HOLX is holding a Forward P/E ratio of 8.94. For comparison, its industry has an average Forward P/E of 42.38, which means HOLX is trading at a discount to the group.
We can also see that HOLX currently has a PEG ratio of 0.94. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 3.07 at yesterday's closing price.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 207, putting it in the bottom 19% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know
Hologic (HOLX - Free Report) closed at $69.64 in the latest trading session, marking a +0.9% move from the prior day. This move outpaced the S&P 500's daily gain of 0.34%.
Prior to today's trading, shares of the medical device maker had gained 14.05% over the past month. This has outpaced the Medical sector's gain of 2.22% and the S&P 500's gain of 2.71% in that time.
Investors will be hoping for strength from HOLX as it approaches its next earnings release, which is expected to be July 28, 2021. In that report, analysts expect HOLX to post earnings of $1.12 per share. This would mark year-over-year growth of 49.33%. Our most recent consensus estimate is calling for quarterly revenue of $1.03 billion, up 25.69% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.72 per share and revenue of $5.11 billion, which would represent changes of +93.97% and +35.36%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for HOLX. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.42% lower. HOLX is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, HOLX is holding a Forward P/E ratio of 8.94. For comparison, its industry has an average Forward P/E of 42.38, which means HOLX is trading at a discount to the group.
We can also see that HOLX currently has a PEG ratio of 0.94. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 3.07 at yesterday's closing price.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 207, putting it in the bottom 19% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.